Cardiff Oncology Inc (NASDAQ:CRDF) does about 1.16M shares in volume on a normal day but saw 1858413 shares change hands in the recent trading day. The company now has a market cap of 286.06M USD. Its current market price is $4.30, marking an increase of 11.40% compared to the previous close of $3.86. The 52 week high reached by this stock is $5.64 whilst the lowest price level in 52 weeks is $2.01.
The consensus objective for the share price is $14.40, suggesting that the stock has a potential upside of 70.14% over the period.
FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on September 06, 2024 when Craig Hallum initiated the stock to “Buy” and issued a price target of $8. Robert W. Baird initiated its price target at $19.
The current price level is 32.47%, 45.08%, and 32.64% away from its SMA20, SMA50, and SMA200 respectively, with the CRDF price moving below the 50-day SMA on current market day. Cardiff Oncology Inc (CRDF) stock is up 22.51% over the week and 61.65% over the past month. Its price is -0.92% year-to-date and 44.30% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at -0.2 and -0.85 for whole year. Expected sales for next quarter are $100k, which analysts say will come at $389.57k for the current fiscal year and next year at $285.71k. In addition, estimates put the company’s current quarterly revenue at an average of $100k.
To reach the target analysts have set, the stock logically needs to grow 70.14 percent from here.
Outstanding shares total 66.53M with insiders holding 5.64% of the shares and institutional holders owning 45.31% of the company’s common stock. The company has a return on investment of -68.35% and return on equity of -74.15%. The beta has a value of 1.58. Price to book ratio is 4.04 and price to sales ratio is 484.85.
